



## Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-<sub>XL</sub>

Jung Jin Hwang<sup>1,2</sup> · Yong Sook Kim<sup>2</sup> · Taelim Kim<sup>2</sup> · Mi Joung Kim<sup>2</sup> · In Gab Jeong<sup>3</sup> · Je-Hwan Lee<sup>4</sup> · Jene Choi<sup>5</sup> · Sejin Jang<sup>5</sup> · Seonggu Ro<sup>6</sup> · Choung-Soo Kim<sup>3</sup>

Published online: 2 April 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

**Correction to: Invest New Drugs (2012) 30:1434–1442**  
<https://doi.org/10.1007/s10637-011-9718-1>

The blots of control and docetaxel for caspase-9, caspase-3, caspase-8, Bcl-<sub>XL</sub>, and tubulin in the Figure 4f were reused from Figure 4 of our previous paper published in *Journal of Urology* in 2010 (<https://doi.org/10.1016/j.juro.2010.07.035>).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s10637-011-9718-1>

---

✉ Choung-Soo Kim  
cskim@amc.seoul.kr

<sup>1</sup> Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

<sup>2</sup> Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

<sup>3</sup> Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul 05505, South Korea

<sup>4</sup> Department of Internal Medicine & Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

<sup>5</sup> Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

<sup>6</sup> PiMedBio, Inc., Seoul 06367, South Korea